HDL in sepsis - risk factor and therapeutic approach

Emily E. Morin, Ling Guo, Anna Schwendeman, Xiang An Li

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

High-density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40-70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAI) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAI in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.

Original languageEnglish
Article number244
JournalFrontiers in Pharmacology
Volume6
Issue numberOCT
DOIs
StatePublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 Morin, Guo, Schwendeman and Li.

Keywords

  • Apolipoprotein A-1 (ApoA1)
  • High-density lipoprotein (HDL)
  • Lipopolysaccharide (LPS)
  • Sepsis
  • Sepsis therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'HDL in sepsis - risk factor and therapeutic approach'. Together they form a unique fingerprint.

Cite this